INVESTORS

Press Releases


November 10, 2022
- Raymond F. Schinazi , Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company’s Scientific Advisory Board (SAB) DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex...
November 3, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes...
September 2, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities...
Displaying 1 - 10 of 31